Stocks

Magazine articles on individual stocks, valuation, accounting standards, IPO's, brokerages, exchanges.

Old Articles: <Older 25021-25030 Newer>

The Motley Fool July 31, 2007 David Lee Smith	Southern Talk for Income Investors Investors, despite Southern Company's solid results, it's too early to get a definitive grip on general public utility trends for the quarter.
The Motley Fool July 31, 2007 Ryan Fuhrmann	Ugly Quarter at Avon Investors, did Avon just take a step back from its restructuring progress?
The Motley Fool July 31, 2007 Lawrence Rothman	Not Buying Rent-A-Center As spending slows down, so do the earnings at this company. Investors can take little consolation in the top and bottom lines coming in within management's guidance.
The Motley Fool July 31, 2007 Katrina Chan	Fast Fool Facts: IAC Grudgingly Adjusts Informative earnings highlights in a timely manner: Interactive conglomerate IAC/InterActiveCorp reported second-quarter 2007 earnings.
The Motley Fool July 31, 2007 Emil Lee	iStar Escapes the Credit Minefield iStar Financial's perceived credit risk has dragged down its stock price, although in reality the commercial real estate lender has very different risk exposure from subprime residential lenders.
The Motley Fool July 31, 2007 Rick Aristotle Munarriz	Starbucks Jams to XM Let the merging begin. XM begins to adjust its stations in preparation of its proposed merger with Sirius Satellite Radio, with some being reintroduced with branded names, such as Hear Music, now called Starbucks XM Cafe.
The Motley Fool July 31, 2007 Anders Bylund	Measuring the Years by Sun Dial: Fool by Numbers Sun Microsystems turns in a good quarter, and its first profitable fiscal year since 2001. The turnaround plans seem to finally be taking effect.
The Motley Fool July 31, 2007 Seth Jayson	Pegasus in Pieces The latest Pegasus Wireless plan looks like a management attempt to slip away from the disaster it created. Where is the SEC?
The Motley Fool July 31, 2007 Anders Bylund	Tequila Sun-Rise It's time to celebrate at Sun Microsystems, as management commitment to fiscal discipline leads to expanded gross margins and steady sales performance.
The Motley Fool July 31, 2007 Brian Lawler	Avandia Can Stay An FDA advisory panel votes to allow GlaxoSmithKline's top diabetes compound, Avandia, to remain on the market.
<Older 25021-25030 Newer> Return to current articles.